A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
← catalyst calendarNCT06905873 · readout in 134 d
Sponsored by Forte Biosciences, Inc. (industry) · FBRX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
64estimated
Sites
6
Countries
Australia, New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-25 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Vitiligo
Interventions
- Drug: FB102
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse events (TEAEs) and Serious Adverse events (SAE) following treatment with FB102
measured Upto 16 Weeks post first dose administration
Percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI)
measured Upto 16 Weeks post first dose administration
Number of participants with percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI)
measured Upto 16 Weeks post first dose administration
Permalink · FBRX's whole pipeline · Catalyst calendar · Every registered study · What changed